Table 1. Effect modification of AGXT2 and 4q25 variants on atrial fibrillation in LURIC.
| AF risk factor | Risk factor cases/controls | AF cases/controls | AGXT2 rs37369 (T) |
AGXT2 rs16899974 (A) |
4q25 rs6817105 (C) |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ORint | (95% CI) | p | ORint | (95% CI) | p | ORint | (95% CI) | p | |||
| Arterial hypertension | 1,721/1,202 | 381/2,542 | 0.99 | (0.56–1.74) | 0.98 | 0.88 | (0.60–1.28) | 0.49 | 0.68 | (0.46–1.02) | 0.065 |
| Diabetes | 1,181/1,742 | 381/2,542 | 0.81 | (0.46–1.40) | 0.45 | 0.82 | (0.56–1.19) | 0.30 | 0.91 | (0.61–1.36) | 0.65 |
| Valvular heart disease | 518/2,405 | 381/2,542 | 0.45 | (0.23–0.86) | 0.015 | 0.46 | (0.30–0.71) | 0.00043 | 1.00 | (0.63–1.59) | 0.99 |
| Aortic stenosis | 146/2,405 | 272/2,279 | 0.45 | (0.09–2.19) | 0.32 | 0.46 | (0.18–1.15) | 0.096 | 1.46 | (0.57–3.73) | 0.43 |
| Aortic insufficiency | 80/2,403 | 269/2,214 | 0.18 | (0.02–1.58) | 0.12 | 0.38 | (0.14–1.05) | 0.063 | 1.37 | (0.47–4.03) | 0.57 |
| Mitral stenosis | 16/2,405 | 260/2,161 | 0.10 | (0.01–1.18) | 0.068 | 0.19 | (0.02–1.59) | 0.13 | 0.44 | (0.08–2.35) | 0.34 |
| Mitral insufficiency | 225/2,394 | 315/2,304 | 0.36 | (0.15–0.88) | 0.025 | 0.48 | (0.27–0.85) | 0.012 | 0.88 | (0.47–1.63) | 0.68 |
| Other | 34/2,403 | 262/2,175 | 2.66 | (0.42–16.9) | 0.30 | 0.83 | (0.25–2.76) | 0.76 | 0.39 | (0.07–2.01) | 0.26 |
| Cardiomyopathy | 307/2,616 | 381/2,542 | 0.79 | (0.37–1.68) | 0.54 | 0.61 | (0.38–0.99) | 0.043 | 1.31 | (0.75–2.27) | 0.34 |
| Ischemic | 134/2,612 | 326/2,420 | 0.62 | (0.21–1.81) | 0.38 | 0.58 | (0.29–1.16) | 0.12 | 1.10 | (0.52–2.34) | 0.79 |
| Dilated | 147/2,614 | 335/2,426 | 0.76 | (0.25–2.26) | 0.62 | 0.46 | (0.24–0.90) | 0.024 | 1.34 | (0.62–2.91) | 0.46 |
| Restricted | 24/2,616 | 296/2,344 | 1.76 | (0.10–32.5) | 0.70 | 2.52 | (0.46–13.8) | 0.29 | 0.67 | (0.08–5.73) | 0.71 |
| Myocardial infarction | 1,217/1,706 | 381/2,542 | 1.43 | (0.81–2.51) | 0.21 | 1.22 | (0.82–1.80) | 0.33 | 0.85 | (0.55–1.30) | 0.46 |
| CVD event (stroke/TIA) | 264/2,659 | 381/2,542 | 1.27 | (0.58–2.78) | 0.55 | 1.53 | (0.86–2.74) | 0.15 | 1.18 | (0.64–2.18) | 0.59 |
Statistics: Results are from logistic regression analyses adjusted for age, sex and BMI. Interaction effects on a multiplicative scale (ORint) per one minor allele increase assuming additive genetic model are shown. ORint = 1 means no interaction on a multiplicative scale.
Notes: In the subgroup analyses of valve disease and cardiomyopathy, controls did not have any valvular disease or cardiomyopathy, respectively.
Abbreviations: CVD, cerebrovascular disease; TIA, transient ischemic attack.